Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study
Vaxcyte stock catapulted Monday after its experimental pneumococcal vaccine proved it's not inferior to marketed shots from Pfizer and Merck.
The post Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study appeared first on Investor's Business Daily .